報價延遲最少15分鐘:2024/05/09 23:39 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.77 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.28/--
|
|
企業價值
10.29M
|
| 資產負債 |
|
每股賬面淨值
-1.10
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/05/09 23:39 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Chromocell Therapeutics Corp is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain and other associated medical conditions. The company's initialclinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic neuropathic pain and eye pain. The Company's portfolio also includes pre-clinical work on other sodium channel receptor subtypes, and the company intends to explore these and other compounds for the treatment of additional pain indications. |